Program
Oxycodone
Also written as “Reformulated OXY (oxycodone HCl)”, “Oxycodone/Naloxone” and “oxycodone hydrochloride”.
Its studies are mostly in Pain · Neoplasms · Osteoarthritis · Cancer Pain · Chronic Pain, led by 13 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Mundipharma | 200 open or running | phase 4since Mar 8, 2011 | Jul 27, 2007 | none ahead |
| Knoa Pharma | 120 open or running | phase 3since Apr 6, 2006 | Apr 6, 2006 | none ahead |
| Pain Therapeutics | 120 open or running | phase 3since Mar 13, 2012 | Aug 12, 2008 | none ahead |
| Pfizer | 60 open or running | phase 4since Jun 8, 2007 | Jun 8, 2007 | none ahead |
| Egalet | 30 open or running | phase 3since Nov 10, 2015 | Dec 2, 2008 | none ahead |
| Keenova Therapeutics | 30 open or running | phase 1since Feb 26, 2009 | Feb 26, 2009 | none ahead |
| Teva Pharmaceutical Industries | 20 open or running | phase 1since Mar 17, 2009 | Mar 17, 2009 | none ahead |
| biodelivery-sciences-international | 10 open or running | phase 1since Jun 21, 2019 | Jun 21, 2019 | none ahead |
| elite-laboratories-inc | 10 open or running | phase 3since Feb 17, 2015 | Feb 17, 2015 | none ahead |
| gl-pharm-tech-corporation | 10 open or running | phase 1since Mar 19, 2012 | Mar 19, 2012 | none ahead |
| Indivior Pharmaceuticals | 10 open or running | phase 1since Nov 16, 2018 | Nov 16, 2018 | none ahead |
| napp-pharmaceuticals-limited | 10 open or running | phase 4since Nov 3, 2008 | Nov 3, 2008 | none ahead |
| vistapharm-inc | 10 open or running | phase 4since Jul 3, 2013 | Jul 3, 2013 | none ahead |
Also a collaborator on its studies: pra-health-sciences and Grünenthal.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Feb 20, 2008.
- Feb 7, 2014Phase 1 study in HealthyPain Therapeutics · NCT02059915 · 134 enrolled · United States
- Mar 13, 2014Phase 1 study in HealthyPain Therapeutics · NCT02089295 · 18 enrolled · United States
- Apr 16, 2014Phase 1 study in HealthyPain Therapeutics · NCT02117583 · 34 enrolled · United States
- Jun 10, 2014Phase 1 study in HealthyPain Therapeutics · NCT02165930 · 17 enrolled · United States
- Oct 13, 2014Phase 3 study in Bronchiolitis Obliterans SyndromeMundipharma · NCT02321397 · 155 enrolled · Germany
- Feb 17, 2015elite-laboratories-inc's first study: phase 3 study in Substance Withdrawal SyndromeNew to elite-laboratories-incelite-laboratories-inc · NCT02391571 · 26 enrolled · United States
- Nov 10, 2015Phase 3 study in Chronic PainEgalet · NCT02603705 · 281 enrolled · United States
- Jan 18, 2016Phase 4 study in Cancer PainMundipharma · NCT02660229 · 66 enrolled · Korea, Republic of
- Mar 8, 2016Phase 3 study in Moderate-to-severe Chronic Low Back PainEgalet · NCT02716857 · 549 enrolled · United States
- May 22, 2017Phase 4 study in NeoplasmsMundipharma · NCT03176121 · 73 enrolled · Taiwan
- Jun 1, 2017Phase 4 study in NeoplasmsMundipharma · NCT03176199 · 30 enrolled · Taiwan
- Mar 7, 2018Phase 1 study in Opioid Abuse NondependentPain Therapeutics · NCT03475862 · 38 enrolled · United States
- Nov 16, 2018Indivior Pharmaceuticals's first study: phase 1 study in HealthyNew to Indivior PharmaceuticalsIndivior Pharmaceuticals · NCT03747341 · 22 enrolled · Netherlands
- Jun 21, 2019biodelivery-sciences-international's first study: phase 1 study in Respiratory InsufficiencyNew to biodelivery-sciences-internationalbiodelivery-sciences-international · NCT03996694 · 19 enrolled · United States
TargetBeta
“Mu opioid receptor agonist; Mu opioid receptor agonist; Mu opioid receptor agonist”ChEMBL 37, by rule
Other programs on OPRM1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Naltrexonerule | orexigen-therapeutics-inc | phase 4 | 42 |
| nalmefenerule | H. Lundbeck | phase 4 | 20 |
| Nalbuphinerule | Trevi Therapeutics | phase 4 | 20 |
| Methadonerule | Merck | phase 4 | 16 |
| cebranopadolrule | Tris Pharma | phase 3 | 18 |
| axelopranrule | glycyx-therapeutics | phase 2 | 8 |
| Alfentanilrule | Sichuan Kelun Pharmaceutical | phase 1 | 1 |
Studies
The newest 60 of 64 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT03996694Respiratory Insufficiency · United States | 1 | Completed | biodelivery-sciences-international | Oct 27, 2019 | 19 |
| NCT03747341Healthy · Netherlands | 1 | Completed | Indivior Pharmaceuticals | Jan 4, 2019 | 22 |
| NCT03475862Opioid Abuse Nondependent · United States | 1 | Completed | Pain Therapeutics | Jul 31, 2017 | 38 |
| NCT03176199Neoplasms · Taiwan | 4 | Completed | Mundipharma | Dec 31, 2018 | 30 |
| NCT03176121Neoplasms · Taiwan | 4 | Completed | Mundipharma | Dec 31, 2018 | 73 |
| NCT02716857Moderate-to-severe Chronic Low Back Pain · United States | 3 | Completed | Egalet | Aug 2017 | 549 |
| NCT02660229Cancer Pain · Korea, Republic of | 4 | Completed | Mundipharma | Jul 2016 | 66 |
| NCT02603705Chronic Pain · United States | 3 | Completed | Egalet | Jun 15, 2017 | 281 |
| NCT02391571Substance Withdrawal Syndrome · United States | 3 | Completed | elite-laboratories-inc | Mar 2015 | 26 |
| NCT02321397Bronchiolitis Obliterans Syndrome · Germany | 3 | Completed | Mundipharma | Mar 2016 | 155 |
| NCT02165930Healthy · United States | 1 | Completed | Pain Therapeutics | Aug 2014 | 17 |
| NCT02117583Healthy · United States | 1 | Completed | Pain Therapeutics | Aug 2014 | 34 |
| NCT02089295Healthy · United States | 1 | Completed | Pain Therapeutics | Jun 2014 | 18 |
| NCT02059915Healthy · United States | 1 | Completed | Pain Therapeutics | Jul 2014 | 134 |
| NCT01986283Substance-Related Disorders · United States | 1 | Completed | Pain Therapeutics | Aug 2014 | 67 |
| NCT01924676Healthy · United States | 1 | Completed | Pain Therapeutics | Oct 2013 | 18 |
| NCT01918098Non Cancer Pain · China | 3 | Completed | Mundipharma | Mar 30, 2017 | 230 |
| NCT01959204Pain · United States | 4 | Completed | vistapharm-inc | Aug 21, 2019 | 97 |
| NCT01885182Neoplasms · China | 3 | Completed | Mundipharma | Aug 30, 2015 | 232 |
| NCT01825447Healthy · United States | 1 | Completed | Pfizer | Sep 2013 | 89 |
| NCT01811186Chronic Pain · Korea, Republic of | 4 | Completed | Mundipharma | Jan 2014 | 261 |
| NCT01717027Healthy · United States | 1 | Completed | Pain Therapeutics | Jan 2013 | 19 |
| NCT01811238Spinal Disorders | 4 | Completed | Mundipharma | Apr 2013 | 240 |
| NCT01719757Neoplasms · Korea, Republic of | 4 | Completed | Mundipharma | Oct 2013 | 359 |
| NCT01675635Pain, Postoperative | 3 | Completed | Mundipharma | Jun 2012 | 240 |
| NCT01675622Neoplasms | 3 | Completed | Mundipharma | Jun 2012 | 242 |
| NCT01568450Healthy · Korea, Republic of | 1 | Completed | gl-pharm-tech-corporation | Apr 2012 | 24 |
| NCT01557257Management of Moderate to Severe Pain · United States | 1 | Completed | Pfizer | May 2012 | 13 |
| NCT01559701Pain | 3 | Completed | Pain Therapeutics | Feb 2008 | 823 |
| NCT01552863Pain · United States | 1 | Completed | Pain Therapeutics | Sep 2012 | 21 |
| NCT01552850Pain · Singapore | 1 | Completed | Pain Therapeutics | Jun 2012 | 18 |
| NCT01530542Agnosia · United States | 1 | Completed | Pfizer | Sep 2010 | 35 |
| NCT01643772Pain · China | 1 | Completed | Mundipharma | Jul 2012 | 61 |
| NCT01482936Pain · China | 1 | Completed | Mundipharma | Apr 2011 | 44 |
| NCT01439100Parkinson Disease · Czech Republic, Germany, Hungary and more | 3 | Completed | Mundipharma | Aug 2013 | 172 |
| NCT01428583Chronic Noncancer Pain · United States | 3 | Completed | Pfizer | May 2012 | 395 |
| NCT01438567Pain · United Kingdom | 3 | Completed | Mundipharma | Feb 2014 | 270 |
| NCT01369615Pain · United States, Israel | 3 | Completed | Knoa Pharma | Dec 2013 | 23 |
| NCT01313780Neoplasms · Korea, Republic of | 4 | Completed | Mundipharma | Oct 2013 | 128 |
| NCT01304134Other Acute Postoperative Pain · China | 3 | Completed | Mundipharma | Aug 2010 | 240 |
| NCT01192295Pain · United States, Greece, Hungary and more | 3 | Completed | Knoa Pharma | Jul 2014 | 155 |
| NCT01167699Pain · Belgium | 3 | Completed | Mundipharma | Apr 2011 | 174 |
| NCT01101321Healthy · United States | 1 | Completed | Knoa Pharma | Aug 2008 | 58 |
| NCT01101308Healthy · United States | 1 | Completed | Knoa Pharma | Aug 2008 | 55 |
| NCT01101191Healthy · United States | 1 | Completed | Knoa Pharma | Oct 2007 | 84 |
| NCT01101178Healthy · United States | 1 | Completed | Knoa Pharma | Nov 2007 | 79 |
| NCT01101165Healthy · United States | 1 | Completed | Knoa Pharma | Apr 2007 | 92 |
| NCT01100320Healthy Volunteers · United States | 1 | Completed | Knoa Pharma | Mar 2007 | 88 |
| NCT01100086Healthy Volunteers · United States | 1 | Completed | Knoa Pharma | Mar 2007 | 84 |
| NCT01099709Healthy Volunteers · United States | 1 | Completed | Knoa Pharma | Mar 2007 | 85 |
| NCT00864526Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Oct 2006 | 40 |
| NCT00864357Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Oct 2006 | 40 |
| NCT00853736Healthy · United States | 1 | Completed | Keenova Therapeutics | Feb 2003 | 23 |
| NCT00853320Healthy · United States | 1 | Completed | Keenova Therapeutics | Feb 2003 | 38 |
| NCT00853216Healthy · United States | 1 | Completed | Keenova Therapeutics | Feb 2003 | 38 |
| NCT00801788Pain · Canada | 1 | Completed | Egalet | Oct 2008 | 16 |
| NCT00784810Osteoarthritis · United Kingdom | 4 | Completed | napp-pharmaceuticals-limited | Mar 2010 | 247 |
| NCT00743587Osteoarthritis Thumbs · Belgium | 1 | Completed | Pfizer | Mar 2009 | 36 |
| NCT00734461Opioid-Related Disorders · United States | 2 | Completed | Pain Therapeutics | Mar 2009 | 14 |
| NCT00626600Cancer Pain · United Kingdom | 3 | Terminated | Mundipharma | May 2009 | 33 |
How it is read
Names in the registry
- “Oxycodone”, 43 entries
- “Reformulated OXY (oxycodone HCl)”, 6 entries
- “Oxycodone/Naloxone”, 5 entries
- “oxycodone hydrochloride”, 4 entries
- “Oxycodone hydrochloride”, 3 entries
Conditions, from the studies’ own filings
- Pain, 15 studies
- Neoplasms, 7 studies
- Osteoarthritis, 4 studies
- Cancer Pain, 3 studies
- Chronic Pain, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.